Article

A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1R132 Mutations

2016-12-02

Abstract excerpt

Abstract Introduction: Isocitrate dehydrogenase (IDH) enzymes catalyze the NADP-dependent interconversion of isocitrate and α-ketoglutarate. R132* IDH1 mutations lead to cellular accumulation of 2-hydroxyglutarate (2-HG), an oncometabolite that promotes tumorigenesis. IDH1 mutations are found in glioma (~80%), chondrosarcoma (~50%), cholangiocarcinoma (~20% intrahepatic), acute myeloid leukemia (AML; ~6-9%), and m...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 09360078-7bff-56fd-8822-8e2ddffa2be9
DOI: 10.1182/blood.v128.22.1073.1073

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1R132 MutationsDOI 10.1182/blood.v128.22.1073.1073Read

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant CancersSemantic proximity Read

Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors.Semantic proximity Read

Clinical development of IDH1 inhibitors for cancer therapy.Semantic proximity Read

HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study.Semantic proximity Read

Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 InhibitorSemantic proximity Read

More than just another IDH inhibitor: Insights from the HMPL-306 phase 1 trial.Semantic proximity Read

Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer.Semantic proximity Read

Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 StudySemantic proximity Read

Ivosidenib: First Global ApprovalSemantic proximity Read

Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of gliomaSemantic proximity Read

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.Semantic proximity Read

HMPL-306 (Ranosidenib): The Next Frontier in mIDH Cancer TherapySemantic proximity Read